{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T19:55:32Z","timestamp":1720468532082},"reference-count":134,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T00:00:00Z","timestamp":1313539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1002\/ajh.22097","type":"journal-article","created":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T15:24:44Z","timestamp":1308065084000},"page":"811-819","source":"Crossref","is-referenced-by-count":6,"title":["Chronic myeloid leukemia 2011: Successes, challenges, and strategies\u2014Proceedings of the 5th annual BCR\u2010ABL1 positive and BCR\u2010ABL1 negative myeloproliferative neoplasms workshop"],"prefix":"10.1002","volume":"86","author":[{"given":"Tariq I.","family":"Mughal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quint\u00e1s\u2010Cardama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Skorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,17]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00454-8"},{"key":"e_1_2_12_4_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib [abstract]","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13529"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_12_7_2","first-page":"76","article-title":"International randomized study of interferon versus STI571 (IRIS) 7\u2010year follow\u2010up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib (IM)","volume":"112","author":"O'Brien SG","year":"2008","journal-title":"Blood"},{"key":"e_1_2_12_8_2","first-page":"315","article-title":"Principal long\u2010term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase","volume":"4","author":"Mughal TI","year":"2010","journal-title":"Biologics"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13068"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_12_12_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood.V116.21.208.208","article-title":"An ongoing phase 3 study of bosutinib (SKI\u2010606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"116","author":"Gambacorti\u2010Passerini C","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.s.006"},{"key":"e_1_2_12_16_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A phase I trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings","volume":"116","author":"Cortes J","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.03.003"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2780"},{"key":"e_1_2_12_22_2","doi-asserted-by":"crossref","first-page":"883a","DOI":"10.1182\/blood.V116.21.883.883","article-title":"Persistence of BCR\u2010ABL\u2010expressing leukemic stem cells in chronic myeloid leukemia (CML) patients in complete remission with undetectable molecular disease","volume":"116","author":"Chomel J\u2010C","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_23_2","doi-asserted-by":"crossref","first-page":"885a","DOI":"10.1182\/blood.V116.21.885.885","article-title":"Whole\u2010transcriptome sequencing in chronic myeloid leukemia reveals novel gene mutations that may be associated with disease pathogenesis and progression","volume":"116","author":"Soverini S","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_24_2","doi-asserted-by":"crossref","first-page":"884a","DOI":"10.1182\/blood.V116.21.884.884","article-title":"A comprehensive deep\u2010sequencing study of blast crisis chronic myeloid leukemia (CML) reveals new insights into molecular heterogeneity and detects mutations in 12 different genes in 82.5% of cases","volume":"116","author":"Grossmann V","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_25_2","doi-asserted-by":"crossref","first-page":"202a","DOI":"10.1182\/blood.V116.21.202.202","article-title":"BCL6 is required for maintenance of leukemia\u2010initiating cells in chronic myeloid leukemia","volume":"116","author":"Hurtz C","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_26_2","doi-asserted-by":"crossref","first-page":"201a","DOI":"10.1182\/blood.V116.21.201.201","article-title":"The Scd1 gene functions as a tumor suppressor in leukemia stem cells","volume":"116","author":"Zhang H","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_27_2","doi-asserted-by":"crossref","first-page":"514a","DOI":"10.1182\/blood.V116.21.514.514","article-title":"Inhibition of chronic myeloid leukemia stem cells by the combination of the Hedgehog pathway inhibitor LDE225 with nilotinib","volume":"116","author":"Zhang B","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_28_2","doi-asserted-by":"crossref","first-page":"199a","DOI":"10.1182\/blood.V116.21.199.199","article-title":"JAK2\u2010mediated extrinsic survival of CML stem cells: Exploring the potential combination of BCR\u2010ABL and JAK2 inhibitors in vivo","volume":"116","author":"Traer E","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_29_2","doi-asserted-by":"crossref","first-page":"515a","DOI":"10.1182\/blood.V116.21.515.515","article-title":"BCR\u2010ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A\u2010controlled JAK2 activation and is sensitive to FTY720 treatment","volume":"116","author":"Neviani P","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_30_2","doi-asserted-by":"crossref","first-page":"516a","DOI":"10.1182\/blood.V116.21.516.516","article-title":"The pan Bcl\u20102 family inhibitor 97C1 targets blast crisis chronic myeloid leukemia stem cells but spares normal cord blood progenitor cells","volume":"116","author":"Goff D","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4687"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5819"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093617"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100268"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147744"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212969"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.01.008"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403158"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403664"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4406"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04200.x"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01168.x"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2184.2001.00195.x"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.67.783.87"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_12_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_12_52_2","first-page":"143","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML\u2010CP)","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_12_54_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) in the DASISION trial: 18\u2010month follow\u2010up","volume":"116","author":"Shah N","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_55_2","first-page":"LBA\u20106","article-title":"A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): The S0325 intergroup trial","volume":"116","author":"Radich JP","year":"2010","journal-title":"Blood (ASH meeting abstracts)"},{"key":"e_1_2_12_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_12_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_12_58_2","first-page":"464","article-title":"Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: Clinical response, safety, and long\u2010term outcomes","volume":"114","author":"Kantarjian HM","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_12_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_2_12_61_2","first-page":"144","article-title":"Efficacy of nilotinib in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)\u2010positive chronic myelogenous leukemia in early chronic phase (CML\u2010CP) [abstract]","volume":"114","author":"Cortes J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_62_2","doi-asserted-by":"crossref","first-page":"487s","DOI":"10.1200\/jco.2010.28.15_suppl.6501","article-title":"Comparison of nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): ENESTnd beyond one year","volume":"28","author":"Larson RA","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_63_2","first-page":"459","article-title":"Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): ENESTnd beyond 1 year","volume":"95","author":"Hochhaus A","year":"2010","journal-title":"Haematologica"},{"key":"e_1_2_12_64_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed CML\u2010CP","volume":"116","author":"Hughes TP","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_65_2","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V116.21.3430.3430","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio G","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_66_2","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood.V116.21.3431.3431","article-title":"Nilotinib lowers the incidence of BCR\u2010ABL mutations and improves the molecular response kinetics compared with imatinib in patients (Pts) with newly diagnosed chronic myeloid leukemia (CML)","volume":"116","author":"Hochhaus A","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.032"},{"key":"e_1_2_12_68_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 19 imatinib\u2010resistant BCR\/ABL mutants","volume":"3","author":"Redaelli S","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_69_2","first-page":"375","article-title":"SKI\u2010606, a 4\u2010anilino\u20103\u2010quinolinecarbanitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas J","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_12_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"e_1_2_12_71_2","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V110.11.2930.2930","article-title":"Synergistic activity of the novl Src\/Abl inhibitor bosutinib in combination with imatinib","volume":"110","author":"Redaelli S","year":"2007","journal-title":"Blood"},{"key":"e_1_2_12_72_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V110.11.733.733","article-title":"Efficacy and safety of bosutinib (SKI\u2010606) among patients with chronic phase Ph+ chronic myelogenous leukemia","volume":"110","author":"Cortes J","year":"2007","journal-title":"Blood"},{"key":"e_1_2_12_73_2","first-page":"7001","article-title":"Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"26","author":"Bruemmendorf TH","year":"2008","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_12_74_2","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/jco.2010.28.15_suppl.6509","article-title":"Safety and efficacy of bosutinib in patients with AP and BP CML and Ph positive ALL following resistance\/intolerance to imatinib and other TKIs: Update from study SKI\u2010200","volume":"28","author":"Gambacorti\u2010Passerini C","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_75_2","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1200\/jco.2010.28.15_suppl.6502","article-title":"Safety and efficacy of bosutinib (SKI\u2010606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)","volume":"28","author":"Cortes JE","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_76_2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.V116.21.892.892","article-title":"Bosutinib as third\u2010line treatment for chronic phase chronic myeloid leukemia following failure of second\u2010line therapy with dasatinib or nilotinib","volume":"116","author":"Khoury HJ","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810133191506"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.16.2775"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_12_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"issue":"1","key":"e_1_2_12_81_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V112.11.305.305","article-title":"Line treatment of adult Ph positive acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study","volume":"112","author":"Foa R","year":"2008","journal-title":"Blood"},{"key":"e_1_2_12_82_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21615"},{"issue":"1","key":"e_1_2_12_83_2","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood.V112.11.2920.2920","article-title":"Dasatinib (Sprycel) and chemotherapy for first\u2010line treatment in elderly patients with de novo Philadelphia positive ALL: Results of the first 22 patients included in the EWALL\u2010Ph\u201001 trial [on behalf of the European Working Group on Adult ALL (EWALL)]","volume":"112","author":"Rousselot P","year":"2008","journal-title":"Blood"},{"key":"e_1_2_12_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.007"},{"key":"e_1_2_12_85_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1389"},{"key":"e_1_2_12_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404320"},{"key":"e_1_2_12_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4386"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_2_12_89_2","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2010.28.15_suppl.6506","article-title":"Long\u2010term outcome after hyper\u2010CVAD and imatinib (IM) for de novo or minimally treated Philadelphia\u2010chromosome positive acute lymphoblastic leukemia (Ph\u2010ALL)","volume":"28","author":"Thomas DA","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23666"},{"key":"e_1_2_12_91_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.546917"},{"issue":"1","key":"e_1_2_12_92_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood.V114.22.837.837","article-title":"Phase II study of combination of the hypercvad regimen with dasatinib in the front line therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL)","volume":"114","author":"Ravandi F","year":"2009","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_93_2","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V114.22.2043.2043","article-title":"Combinations of the hypercvad regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia and lymphoid blast phase chronic myeloid leukemia (CML\u2010LB)","volume":"114","author":"Ravandi F","year":"2009","journal-title":"Blood"},{"key":"e_1_2_12_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_2_12_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22631"},{"key":"e_1_2_12_96_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"e_1_2_12_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_12_99_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3373"},{"key":"e_1_2_12_100_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41246"},{"key":"e_1_2_12_101_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.546912"},{"key":"e_1_2_12_102_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.546920"},{"key":"e_1_2_12_103_2","first-page":"21","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"21","author":"Khorashad JS","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_104_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.531"},{"key":"e_1_2_12_105_2","first-page":"15","article-title":"Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression","volume":"15","author":"Brazma D","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"e_1_2_12_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.210"},{"key":"e_1_2_12_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk150"},{"key":"e_1_2_12_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.169"},{"key":"e_1_2_12_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1114"},{"key":"e_1_2_12_110_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_2_12_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(00)00007-8"},{"key":"e_1_2_12_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00220-3"},{"key":"e_1_2_12_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(01)00285-7"},{"key":"e_1_2_12_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(01)00091-4"},{"key":"e_1_2_12_115_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.2.1.41"},{"key":"e_1_2_12_116_2","first-page":"989","article-title":"DNA mismatch repair, microsatellite instability and cancer","volume":"40","author":"Vaish M","year":"2002","journal-title":"Ind J Exp Biol"},{"key":"e_1_2_12_117_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.32.19633"},{"key":"e_1_2_12_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2003.06.002"},{"key":"e_1_2_12_119_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2815"},{"key":"e_1_2_12_120_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1101"},{"key":"e_1_2_12_121_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1941"},{"key":"e_1_2_12_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.78"},{"key":"e_1_2_12_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5742(02)00009-1"},{"key":"e_1_2_12_124_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6858"},{"key":"e_1_2_12_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2005.10.005"},{"key":"e_1_2_12_126_2","first-page":"2791","article-title":"Myeloid leukemias have increased activity of the nonhomologous end\u2010joining pathway and concomitant DNA misrepair that is dependent on the Ku70\/86 heterodimer","volume":"62","author":"Gaymes TJ","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_12_127_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172148"},{"key":"e_1_2_12_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00357-4"},{"key":"e_1_2_12_129_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2922"},{"key":"e_1_2_12_130_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32834399a5"},{"key":"e_1_2_12_131_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9176"},{"key":"e_1_2_12_132_2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.V116.21.1241.1241","article-title":"Is there a clinical benefit for less than a complete cytogenetic response (CCyR) for patients (Pts) with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKI) as second or third line therapy?","volume":"116","author":"Cortes JE","year":"2010","journal-title":"Blood"},{"key":"e_1_2_12_133_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long\u2010term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot F","year":"2007","journal-title":"Blood"},{"key":"e_1_2_12_134_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23238"},{"key":"e_1_2_12_135_2","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1182\/blood.V116.21.2298.2298","article-title":"A more sensitive RQ\u2010PCR to assess complete molecular remission does not allow the prediction of relapse after discontinuation of imatinib in chronic myeloid leukemia","volume":"116","author":"Mahon FX","year":"2010","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.22097","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.22097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:56:46Z","timestamp":1697457406000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.22097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,17]]},"references-count":134,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/ajh.22097"],"URL":"https:\/\/doi.org\/10.1002\/ajh.22097","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,17]]}}}